James Wassil Biography and Net Worth

COO of Vaxcyte

James Wassil M.B.A., M.S. is the Chief Operating Officer at Vaxcyte.

How old is James Wassil?: Mr. Wassil is currently 55 years old. There are 7 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., Senior Vice President of Process Development & Manufacturing, who is 63 years old. Learn More on James Wassil's age.
How do I contact James Wassil?: The corporate mailing address for Mr. Wassil and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on James Wassil's contact information.
Has James Wassil been buying or selling shares of Vaxcyte?: James Wassil has not been actively trading shares of Vaxcyte over the course of the past ninety days. Learn More on James Wassil's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 48 times. They sold a total of 430,090 shares worth more than $33,820,640.21. The most recent insider tranaction occured on November, 7th when CEO Grant Pickering sold 2,366 shares worth more than $245,803.74. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 11/7/2024.

James Wassil Insider Trading History at Vaxcyte

James Wassil Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $99.38

$98.68

$103.30

50 Day Range

MA: $112.01

$102.70

$117.93

2 Week Range

Now: $99.38

$46.16

$121.06

Volume

1,547,424 shs

Average Volume

844,264 shs

Market Capitalization

$12.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.